PTGX

Protagonist Therapeutics, Inc. - Common Stock (PTGX)

About Protagonist Therapeutics, Inc. - Common Stock (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$142.18

Daily low

$137.99

Price at open

52 Week High

$160.81

52 Week Low

$65.56

Market cap

9.1B

Dividend yield

Volume

985

Avg. volume

790,737

P/E ratio

135.88

Protagonist Therapeutics, Inc. - Common Stock News